TUSTIN, Calif., June 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for hepatitis C virus and cancer, today announced that it will present at the Jefferies Life Sciences Conference on June 28, 2006 at 3:00 pm EDT. The conference will be held at the Mandarin Oriental Hotel in New York City.
Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.
Mr. King's presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.peregrineinc.com. A replay will be available on the Peregrine website and will be archived for approximately 90 days.
About Peregrine
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab (formerly Tarvacin) and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Investors Media The Brod Group Barbara Lindheim & Stephen Gendel (800) 987-8256 GendeLLindheim BioCom Partners ir@peregrineinc.com (212) 918-4650
Peregrine Pharmaceuticals, Inc.CONTACT: Investors, The Brod Group, +1-800-987-8256, ir@peregrineinc.com;or Media, Barbara Lindheim or Stephen Gendel, both of GendeLLindheim BioComPartners, +1-212-918-4650, all for Peregrine Pharmaceuticals, Inc.
